Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
Fatima Tuz Zahra, MD, a hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, presented real-world data from a retrospective study evaluating the effectiveness of oral…
Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses the significant advancements…
In this update, Ashley Yocum, PhD, executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society, provides insights into the Beat AML…
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…
In a presentation at the 2024 International Pathology Day virtual conference, Dr Justin Loke, CRUK/AACR Transatlantic Fellow, University of Birmingham, UK and Dana-Farber Cancer Institute, USA, explains how…
In an interview conducted at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy, Gail J. Roboz, MD, professor of medicine and director of the…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
